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Available online 15 July 2016This study evaluated the performance of a new commercially available multiplex real-time PCR kit Amplidiag®
Bacterial GE in the systematic screening of bacterial pathogens causing gastroenteritis. Stool samples from
1168 patients were analyzed with Amplidiag® Bacterial GE, stool culture, and molecular reference tests, and
the sensitivity and speciﬁcity of Amplidiag® Bacterial GEwere determined by comparing the results to the refer-
ence tests. The evaluation showed good performance for Amplidiag® Bacterial GE: sensitivity and speciﬁcity of
the test was 100/99.7% for Salmonella, 100/99.8% for Yersinia, 98.8/99.2% for Campylobacter, 92.9/100% for Shigel-
la/EIEC, 100/99.9% for EHEC, 92.9/99.8% for ETEC, 98.9/99.2% for EPEC, and 100/99.8% EAEC, respectively. When
compared with stool culture, Amplidiag® Bacterial GE was found to be more sensitive. This study suggests that
Amplidiag® Bacterial GE is suitable for screening bacterial pathogens from stool samples. However, this study
only demonstrates the performance of Amplidiag® Bacterial GE in low endemic settings, as the number of pos-
itive ﬁndings in this study was relatively low.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
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There are almost 1.7 billion cases of diarrhea in theworld every year
(WorldHealth Organization (WHO), 2013). Diarrhea is the second lead-
ing cause of child morbidity and mortality in the developing countries,
and acute diarrhea is one of the most common illnesses for travelers
(World Health Organization (WHO), 2013; Kelly, 2011). Fast and reli-
able diagnosis of gastroenteritis is important for ensuring proper man-
agement of the diarrheal patients. If not treated, some bacterial
pathogens are able to develop persistent gastrointestinal symptoms
(Arenas-Hernández et al., 2012; Connor, 2013; World Health
Organization, 2005). In addition, Campylobacter, Salmonella and Shigella
are strongly linked to the development of reactive arthritis, yet the ef-
fect of proper treatment of gastroenteritis on the incidence of arthritis
is still unclear (Ajene et al., 2013). Then again, inmany instances antimi-
crobials are unnecessarily prescribed for self-limited diarrhea, leading
to higher risk of colonizationwith antimicrobial resistant intestinal bac-
teria (World Health Organization, 2005; Kantele et al., 2015). In addi-
tion, antibiotics can trigger haemolytic uremic syndrome, a life-icrobiology and Immunology,
land.
evmu@utu.ﬁ (E. Munukka),
rolinska.se (M. Ullberg),
. This is an open access article underthreatening condition linked to Shiga toxin producing Escherichia coli
(Tarr et al., 2005; Wong et al., 2012).
When suspecting bacterial gastroenteritis, bacterial culture is the
standard procedure for diagnostics (Bennett and Tarr, 2009; Farthing
and Kelly, 2007). Conventional bacterial culture is relatively reliable
method for systematic screening of bacterial pathogens from stool sam-
ples, but it usually takes several working days to get the ﬁnal results. In
addition, conventional methods are able to detect only a few causative
agents of diarrhea (Fhogartaigh and Dance, 2013). In recent years, mo-
lecular methods for clinical diagnostics have quickly emerged and im-
proved our understanding on the epidemiology of bacterial
gastroenteritis (Fhogartaigh and Dance, 2013; Zhang et al., 2015). For
gastrointestinal pathogen detection, multiplex PCR based methods are
considered most promising. Currently available multiplex PCR assays
differ notably in their detection panels, assay turnaround time and pro-
tocol complexity (Zhang et al., 2015). In comparison to conventional di-
agnostic methods, the majority of the molecular methods have lower
hands-on time, simpler result interpretation and higher sensitivity
(Zhang et al., 2015; de Boer et al., 2010; Biswas et al., 2014; Anderson
et al., 2014).
Amplidiag® Bacterial GE is a novel multiplex real-time PCR kit de-
signed to detect the most common and important bacteria causing bac-
terial gastroenteritis. The test kit has been developed based on
experience from an in-house quantitative PCR test that has been origi-
nally designed for rapid diagnostics of acute travelers' diarrhea, butthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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from stool samples of patients suffering from different gastrointestinal
symptoms (Antikainen et al., 2013). The PCR assay panel includes
eight pathogen targets divided in three multiplex reactions (Table 1).
With Amplidiag® Bacterial GE, pathogens can be detected directly
from DNA isolated from stool samples without the need for stool cul-
ture. The results are gained within a few hours after the sample arrival
in laboratory.
This study analyzed the suitability of Amplidiag® Bacterial GE in sys-
tematic screening of bacterial pathogens from clinical specimens of pa-
tients with distinct gastrointestinal symptoms. The study was
conducted in two clinical microbiology laboratories, one situated in
Turku, Finland, and the other in Stockholm, Sweden. Stool samples
from 1168 patients were analyzed with Amplidiag® Bacterial GE, stool
culture and molecular biology reference tests, and the sensitivity and
speciﬁcity of Amplidiag® Bacterial GE were determined by comparing
the results to the biochemical and molecular methods.
2. Materials and methods
2.1. Sample collection
Stool samples from 1168 individual patients were included in this
study. Sampleswere originally sent to a clinicalmicrobiology laboratory
for stool culture between April 7th 2014 and June 17th 2014. Four hun-
dred and seventy-one samples were collected in Turku while 697 sam-
ples were collected in Stockholm. Ethical approval for using the patient
samples was not required, as the study was considered as a basic labo-
ratory method development for the same, original diagnostic purpose.
No additional sample container or additional informationwas collected,
and no other inconvenience for patients was generated. Only the stool
culture results were reported to customers.
In Turku, clinical specimenswere collected in regular stool jarswith-
out preservatives, while in Stockholm, samples were collected in eSwab
collection tubes (Copan, Italy). Specimens arriving in the laboratory
were cultured and then stored at +4 °C. In Turku, samples older than
three days were excluded from the study to eliminate bias of false neg-
ative culture results due to logistical issues. In addition, samples arriving
in the laboratory on Friday were excluded from the study to avoid bias
caused by a long DNA extraction delay.
The age of the study subjects ranged from 0 to 100 (mean 46 years),
and the sex distributionwas 44%males and 56% females. Clinical history
for the majority of the samples was not available, but as the samples
were originally sent for stool culture, it can be presumed that the pa-
tients either suffered from gastrointestinal symptoms or had recently
received treatment for a gastrointestinal condition.Table 1
Amplidiag® Bacterial GE assay panel.
Origin Gene Channel
Multiplex
1
EHEC stx1, stx2 Green
EHEC/EPEC eae Yellow
Salmonella spp. invA Orange
Ampliﬁcation control Red
Multiplex
2
ETEC est, elt Green
Yersinia
enterocolitica/pseudotuberculosis/pestis
rumB, virF Yellow
Campylobacter jejuni/coli rimM,
gyrB
Orange
Ampliﬁcation control Red
Multiplex
3
Shigella/EIEC ipaH, invE Green
EAEC aggR Yellow
Ampliﬁcation control Red
Abbreviations: EAEC, enteroaggregative E. coli; EHEC, enterohaemorrhagic E. coli; EIEC,
enteroinvasive E. coli; EPEC, enteropathogenic E. coli; ETEC, enterotoxigenic E. coli.2.2. Evaluation workﬂow
All patient samples (n = 1168) were analyzed with stool culture,
Amplidiag® Bacterial GE (Mobidiag Ltd., Finland), and molecular refer-
ence tests: RIDA®GENE Bacterial Stool Panel (R-Biopharm AG, Germa-
ny), genesig® Campylobacter jejuni and Campylobacter coli kits
(Primerdesign Ltd., UK), and an in-house multiplex PCR for the
diarrheagenic E. coli species (Antikainen et al., 2009). In the result anal-
ysis, stool culture was considered as the primary reference method for
the identiﬁcation of Salmonella, Campylobacter, Shigella and Yersinia.
However, if discrepancies between stool culture and Amplidiag® Bacte-
rial GE results occurred, molecular reference tests were considered as
the gold standard. In these cases, RIDA®GENE Bacterial Stool Panel (R-
Biopharm AG, Germany) was the reference test for Salmonella and
Yersinia identiﬁcation, while genesig® Campylobacter jejuni and Cam-
pylobacter coli kits (Primerdesign Ltd., UK) were the reference tests for
Campylobacter identiﬁcation. As no culturemethods for E. coli identiﬁca-
tion were included in this study, the in-house multiplex PCR for
diarrheagenic E. coli species (Antikainen et al., 2009) was considered
as the gold standard for EAEC, EHEC, EIEC, EPEC, and ETEC detection.
2.3. Nucleic acid extraction
Samples included in the Amplidiag® Bacterial GEmethod evaluation
were recorded with Amplidiag ID numbers and the nucleic acid (NA)
extractionwas performed on the followingmorning. An extraction con-
trol, representing cultured Salmonella enterica spp. enterica serovar
Newport (ATCC 6962) cells diluted in PBS, was included in each extrac-
tion series to control the performance of the NA extraction instrument.
In Turku, bacterial NA from stool samples was extracted with MagNA
Pure 96 DNA and Viral NA Large Volume Kit (Roche Diagnostics
GmbH, Germany) following the manufacturer's protocol. Prior to ex-
traction, 150–200 mg of sample material was suspended in 600 μl of
1 × PBS, heated at 100 °C for 10 min, and centrifuged 15 s at 500 ×g.
300 μl of the supernatantwasmixedwith 250 μl ofMagNA Pure Bacteria
Lysis Buffer (Roche Diagnostics GmbH, Germany) and 500 μl of the solu-
tion was used for the extraction. The ﬁnal elution volume after extrac-
tion was 100 μl. In Stockholm, bacterial NA was extracted with
semiautomatic Bullet Stool Kit (DiaSorin, Ireland) following the
manufacturer's instructions. Sample material used for the extraction
was 400 μl, and the ﬁnal elution volume was 100 μl. The NA eluates
were divided into several aliquots, of which one was analyzed with
Amplidiag® Bacterial GE without delay, while the others were stored
at−70 °C until analysis with molecular reference tests.
2.4. Multiplex real-time PCR
Amplidiag® Bacterial GE PCR was performed according to the
manufacturer's instructions. The assay panel included eight diarrhea-
causing bacterial pathogens divided into three multiplex reactions
(Table 1). Master Mix and Assay Mixes 1–3 were ready-to-use. The
amount of template DNA in one reaction was 5 μl, and the total reaction
volumewas 25 μl. Each PCR series included an extraction control, a pos-
itive control mix including templates for all tested targets, and a nega-
tive control. In addition, each reaction included an internal
ampliﬁcation control for the detection of the presence of PCR inhibitors.
In Turku, ampliﬁcation reactions were performed with CFX96 (Bio-
Rad). In Stockholm, PCRwas donewith ABI 7500 FAST qPCR instrument
(Applied Biosystems). Twenty-nine samples could be analyzed in one
PCR run when using 96-well-plates. The raw data was exported to and
analyzed by a fully automated analysis program Amplidiag® Analyzer
(Mobidiag Ltd., Finland). The software normalized minor variations be-
tween reagent batches and different qPCR instruments for data inter-
pretation. The program reported the results in written format,
including potentialwarnings fromextraction controls, positive and neg-
ative controls, and internal ampliﬁcation controls. The Amplidiag®
Fig. 1. The bacterial pathogen ﬁndings with conventional stool culture. The number of
samples reported positive with stool culture was 72 (6%), and the total number of
ﬁnding was 73: 11 Salmonella, 2 Yersinia, 57 Campylobacter, and 3 Shigella.
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interpretation, took approximately 3 h in total, when up to 29 stool sam-
ples were simultaneously analyzed.
3. Results
When the combined results of stool culture andmolecular reference
tests were considered as a gold standard, the sensitivity and speciﬁcity
of Amplidiag® Bacterial GE for clinical stool specimens was 100/99.7%
for Salmonella, 100/99.8% for Yersinia, 98.8/99.2% for Campylobacter,
92.9/100% for Shigella/EIEC, 100/99.9% for EHEC, 92.9/99.8% for ETEC,
98.9/99.2% for EPEC, and 100/99.8% EAEC, respectively (Table 2). All
Amplidiag® Bacterial GE results that went alongwith the gold standard
results were deﬁned as true positive or true negative. Amplidiag® Bac-
terial GE results that could not be conﬁrmed by the reference methods
were determined as false positive or false negative.
Of the 1168 clinical patient samples, 914 (78.3%) were negative for
all studied pathogens with both Amplidiag® Bacterial GE and the gold
standard. One hundred seventy-three samples (14.8%) were positive
for one pathogen, 46 (3.9%) for two pathogens and 13 (1.1%) for three
or more pathogens simultaneously. EPEC and Campylobacter were the
most common ﬁndings; 8.0% of all samples were EPEC positive while
7.3% were Campylobacter positive.
Two hundred thirty-seven (20.3%) of the 1168 clinical specimens
were positive for one or more studied bacterial pathogens with the ref-
erence methods. With Amplidiag® Bacterial GE, the number of positive
samples was 249 (21.3%). When considering the reference methods
being the gold standard, 17 samples would have been diagnosed incor-
rectly positivewith Amplidiag® Bacterial GE: 7 EPEC, 4 Campylobacter, 2
Salmonella, 2 Yersinia, EHEC, and EAEC. In addition, nine samples posi-
tive for one pathogenwith both Amplidiag® Bacterial GE and the refer-
ence methods, had an additional positive call only with Amplidiag®
Bacterial GE (5 Campylobacter, 2 EPEC, Salmonella, ETEC), one sample
positive for two pathogens had an additional positive call for Salmonella
with Amplidiag® Bacterial GE, and one sample positive for two patho-
gens had two additional positive calls (ETEC, EAEC) with Amplidiag®
Bacterial GE. In total, the number of these additional positive calls
with Amplidiag® Bacterial GE was 29. When considering the molecular
reference methods being the gold standard, ﬁve samples were incor-
rectly negative with Amplidiag® Bacterial GE: 2 ETEC, EPEC, Campylo-
bacter, and Shigella/EIEC. However, when compared with stool culture,
no false negative results were detected.
With stool culture, 72 of the 1168 studied clinical specimens were
reported positive: 11 samples were positive for Salmonella, 57 for Cam-
pylobacter, two for Yersinia and three for Shigella (Fig. 1). The total num-
ber of ﬁndings was 73, as one sample was positive for both Salmonella
and Campylobacter. When considering the Amplidiag® Bacterial GE re-
sults that went along with the molecular biology reference tests, the
number of positive specimenswas 232 and the total number of ﬁndingsTable 2
Final results of the Amplidiag® Bacterial GE performance evaluation.
Target Gold Standarda Amplidiag® Bacterial GE
Positive Negative True positiveb True negativ
EHEC 7 1161 7 1160
EPEC 94 1074 94 1065
Salmonella 16 1152 16 1148
ETEC 28 1140 26 1138
Yersinia 2 1166 2 1164
Campylobacter 85 1083 84 1074
Shigella/EIEC 14 1154 13 1154
EAEC 66 1102 66 1100
Abbreviations: EAEC, enteroaggregative E. coli; EHEC, enterohaemorrhagic E. coli; EIEC, enteroi
a Combination of the results of stool culture and molecular reference methods.
b Amplidiag® Bacterial GE consistent with the gold standard results.
c Amplidiag® Bacterial GE not consistent with the gold standard results.was 308 (Fig. 2). Of these ﬁndings, 16 were Salmonella, 84 Campylobac-
ter, 2 Yersinia, and 13 Shigella/EIEC, the total number of ﬁndings for
pathogens traditionally analyzed only with stool culture being 115.
4. Discussion
Based on this study, Amplidiag® Bacterial GE multiplex real-time
PCR kit performs well in the qualitative detection and identiﬁcation of
themost prominent bacterial pathogens associatedwith gastroenteritis.
The kit is easy-to-use, and hands-on time needed is low in comparison
to traditional stool culture. The key ﬁnding of this study is that
Amplidiag® Bacterial GE does not compromise sensitivity when com-
pared to traditional stool culture. In fact, when considering the number
of Salmonella and Campylobacter ﬁndings during the evaluation,
Amplidiag® Bacterial GE clearly rises above stool culture in capability
to identify these pathogens from the patient samples; a total of 32 sam-
ples found positive for Salmonella or Campylobacter with both
Amplidiag® Bacterial GE and the molecular reference methods
remained negative in conventional stool culture. When compared to
the consolidated gold standard results, Amplidiag® Bacterial GE pre-
sented altogether 5 false negative and 29 false positive calls for the stud-
ied pathogens. However, apart from a single false identiﬁcation of C.
upsaliensis as C. coli, the rest of the supposed false positive results
might actually originate from an inability to conﬁrm the low abundant
ﬁndings with the molecular reference methods. This study thus shows
good performance for Amplidiag® Bacterial GE. However, this study
only demonstrates the performance of the method in low endemic set-
tings, as the overall number of the positive ﬁndings was relatively low.
This is probably due to the occasion of the sample collection: the
study was performed in late spring, while in general the bacterial gas-
troenteritis is most prevalent in the warm season, which in Finland
and Sweden is basically limited to summer months July and August.eb False positivec False negativec Sensitivity Speciﬁcity
1 0 100.0% 99.9%
9 1 98.9% 99.2%
4 0 100.0% 99.7%
2 2 92.9% 99.8%
2 0 100.0% 99.8%
9 1 98.8% 99.2%
0 1 92.9% 100.0%
2 0 100.0% 99.8%
nvasive E. coli; EPEC, enteropathogenic E. coli; ETEC, enterotoxigenic E. coli.
Fig. 2. The bacterial pathogen ﬁndings with Amplidiag® Bacterial GE. Only the results
conﬁrmed by the molecular reference tests are presented. The number of positive
samples was 232 (20%), and the total number of ﬁndings was 308: 16 Salmonella, 2
Yersinia, 84 Campylobacter, 13 Shigella/EIEC, 7 EHEC, 94 EPEC, 26 ETEC, and 66 EAEC.
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kits (Zhang et al., 2015), the main advantages of Amplidiag® Bacterial
GE include fast turnaround timewith high throughput, simple result in-
terpretation, and detection of all diarrheagenic pathotypes of E. coli
among other important bacterial pathogens. Even though certain com-
mercial multiplex PCR tests (Spina et al., 2015; Harrington et al.,
2015) are undoubtedly more user-friendly than Amplidiag® Bacterial
GE and other non-integrated qPCR methods, the random access
methods often either possess a limited test panel (Harrington et al.,
2015), or are more suitable for stand-by 24/7 diagnostics rather than
screening of large sample cohorts due to low throughput (Spina et al.,
2015). The general downside of all currently available molecular tests
is the lack of antibiotic resistance information and exact species level
identiﬁcation. To gain these, stool culture and traditional biochemical
methods are still required. However, the resistance testing is not neces-
sary for most gastroenteritis pathogens. Furthermore, stool culture
could be performed after gaining the PCR results, for positive samples
only.
Currently many clinical microbiology laboratories routinely diag-
nose EHEC serotype O157:H7 by bacterial culture, but few laboratories
utilize antigen detection or molecular methods to additionally detect
non-O157:H7 EHEC (Marcon, 2011). In addition, other pathogenic E.
coli variants are often completely overleaped, even though the preva-
lence of various pathotypes is notable in diarrheal patients (Marcon,
2011). PCR tests for the identiﬁcation of diarrheagenic E. coli subtypes
have been developed, but these assay panels are often limited to E. coli
alone (Antikainen et al., 2009; Persson et al., 2007). In fact, themajority
of otherwise comprehensive commercial multiplex real-time PCR
panels exclude at least some of the diarrheagenic E. coli variants
(Zhang et al., 2015). Thus, the ability to detect all diarrheagenic E. coli
pathotypes with Amplidiag® Bacterial GE is a huge advance.
Detection of Campylobacter in multiplex PCR panels is often some-
what overwhelming; some panels detect Campylobacter spp., meaning
that the positive results can represent non-pathogenic Campylobacter
species as well as pathogenic (Zhang et al., 2015). Amplidiag® Bacterial
GE detects themost prevalent pathogenic species C. jejuni and C. coli, ex-
cluding all non-pathogenic species. This makes the result interpretation
easy, but the downside is that rare pathogenic species like C. lari and C.
fetus are also ignored. For Yersinia enterocolitica detection, Amplidiag®
Bacterial GE exploits primers speciﬁc to a plasmid-borne virF gene. As
virF is a virulence gene, Amplidiag®Bacterial GE recognizes only the vir-
ulent strains of the bacterium. This feature is valuable in diagnostics, as
non-pathogenic Y. enterocolitica stains are not detected. Yet, for this
same reason, the performance of Amplidiag® Bacterial GE in Yersinia di-
agnostics cannot be tested with commercial quality control species, as
the virulence plasmid is often missing from the control strains eitherpurposely or due to extensive in vitro cultures (Zheng et al., 2008).
One possible weakness of Amplidiag® Bacterial GE is the lack of
Aeromonas in the assay panel. The role of Aeromonas as a potential en-
teric pathogen is still debated though (Janda and Abbott, 2010), there-
fore justifying the exclusion of the bacterial genus from the assay.
Bacterial culture from stool is unquestionably less expensive than
molecular screening, when looking only at the analytical cost of an indi-
vidual sample. Nevertheless, the hands-on time saved in the laboratory
and the decrease in the answering delay could lower the total cost bur-
den of the health care system. Analyses between conventional stool cul-
ture and commercial multiplex PCR methods have already given
promising results (Halligan et al., 2014; Mortensen et al., 2015), and
for example in Clostridium difﬁcile testing, fast molecular biology
methods have already been found more cost-effective than traditional
methods in hospital-wide scale (Schroeder et al., 2014). However,
more comprehensive economic studies should be performed to reveal
the real cost savings and overall impact of using molecular biology
methods in the clinical process of gastroenteritis diagnosis.
5. Conclusions
This study demonstrates that Amplidiag® Bacterial GE kit is a valu-
able tool in the screening of bacterial pathogens from diarrheal stool
samples, at least in low endemic settings.When compared to traditional
stool culture, Amplidiag® Bacterial GE is evidently faster and needs less
hands-on time, without compromising sensitivity. To take the full ad-
vance out of fast and accurate molecular biologymethods, clinical labo-
ratories should be progressive enough to change their routine
diagnostic traditions.Acknowledgments
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